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Late-onset Alzheimer’s disease (AD; LOAD) is the most common human
neurodegenerative disease, however, the availability and efficacy of disease-modifying
interventions is severely lacking. Despite exceptional efforts to understand disease
progression via legacy amyloidogenic transgene mouse models, focus on disease
translation with innovative mouse strains that better model the complexity of human
AD is required to accelerate the development of future treatment modalities. LOAD
within the human population is a polygenic and environmentally influenced disease
with many risk factors acting in concert to produce disease processes parallel to
those often muted by the early and aggressive aggregate formation in popular mouse
strains. In addition to extracellular deposits of amyloid plaques and inclusions of the
microtubule-associated protein tau, AD is also defined by synaptic/neuronal loss,
vascular deficits, and neuroinflammation. These underlying processes need to be
better defined, how the disease progresses with age, and compared to human-
relevant outcomes. To create more translatable mouse models, MODEL-AD (Model
Organism Development and Evaluation for Late-onset AD) groups are identifying
and integrating disease-relevant, humanized gene sequences from public databases
beginning with APOEε4 and Trem2*R47H, two of the most powerful risk factors
present in human LOAD populations. Mice expressing endogenous, humanized
APOEε4 and Trem2*R47H gene sequences were extensively aged and assayed using
a multi-disciplined phenotyping approach associated with and relative to human AD
pathology. Robust analytical pipelines measured behavioral, transcriptomic, metabolic,
and neuropathological phenotypes in cross-sectional cohorts for progression of disease
Abbreviations: AD, Alzheimer’s disease; ADGC, Alzheimer’s Disease Genetics Consortium; ADNI, Alzheimer’s
Disease Neuroimaging Initiative; ADSP, Alzheimer’s Disease Sequencing Project; AMP-AD, Accelerating Medicines
Partnership—Alzheimer’s Disease; B6, C57BL/6J; BBB, Blood-brain barrier; CNS, Central nervous system; DEG,
Differentially expressed genes; FP, frontal pole brain regions; HDL, high-density lipoproteins; IGAP, International
Genomics of Alzheimer’s Project; LOAD, Late-onset Alzheimer’s disease; LDL, low-density lipoproteins; M2OVE-AD,
Molecular Mechanisms of the Vascular Etiology of Alzheimer’s Disease; MRI, Magnetic resonance imaging; PET, Positron
emission tomography; PHG, parahippocampal gyrus; ROS/MAP, Religious Orders Study and Memory and Aging Project.
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hallmarks at all life stages. In vivo PET/MRI neuroimaging revealed regional alterations
in glycolytic metabolism and vascular perfusion. Transcriptional profiling by RNA-Seq
of brain hemispheres identified sex and age as the main sources of variation between
genotypes including age-specific enrichment of AD-related processes. Similarly, age was
the strongest determinant of behavioral change. In the absence of mouse amyloid plaque
formation, many of the hallmarks of AD were not observed in this strain. However, as a
sensitized baseline model with many additional alleles and environmental modifications
already appended, the dataset from this initial MODEL-AD strain serves an important
role in establishing the individual effects and interaction between two strong genetic risk
factors for LOAD in a mouse host.
Keywords: ApoE4, TREM2, mouse model, MODEL-AD, late-onset AD
INTRODUCTION
Alzheimer’s disease (AD) is the most common form of dementia,
currently affecting 5.8 million patients in the United States
(Alzheimer’s Association, 2020), ∼95% of which are late-onset
(LOAD; Cacace et al., 2016). Unfortunately for patients and their
families, interventions approved to delay or reverse AD-related
neurodegeneration have yet to materialize (U.S. Department
of Health and Human Services, 2021), despite promising new
therapies aimed at decreasing amyloid burden (U.S. Food
and Drug Administration, 2021). LOAD is a heterogeneous
disease defined by a few widely accepted hallmarks: extracellular
amyloid plaques, intracellular tau tangles, vascular dysfunction,
immune activation, synapse loss, neuron death, and cognitive
decline (Blennow et al., 2006). Dissecting the etiology of these
properties in animal models has provided key insights into our
understanding of the disease and strategies to treat AD, however,
human clinical trials of resultant therapeutics have not yielded an
approvable drug.
In 2015, the National Institutes on Aging (NIA) aimed
to accelerate the AD drug testing pipeline by promoting the
design of more predictive preclinical studies that better translate
to human disease (U.S. Department of Health and Human
Services, 2021). Current popular animal models of AD rely on
the expression of transgenic alleles to promote the aggregation
of amyloid plaques or neurofibrillary tangles as drivers of
subsequent disease processes, notably during adolescence and
early adulthood (Sasaguri et al., 2017). Therefore, these
overexpression models do not fully capitulate the breadth of
the disease observed in human patients, particularly elderly
populations; many underlying biological pathways affected in
human disease are not observed in these mice (Logsdon et al.,
2019). From this need, the MODEL-AD (Model Organism
Development and Evaluation for Late-onset AD) consortium
was established to provide the research community with the
next generation of AD animal models (Oblak et al., 2020).
In an effort to design and validate novel mouse models
of LOAD that better mimic human disease, we opted to
create knock-in humanized coding and non-coding LOAD risk
variants expressed at endogenous levels. To implement these
considerations in the development of a new generation of
preclinical animal models, candidate humanized gene variants
or SNPs from a number of public data repositories (ADSP,
AMP-AD, ADGC, ADNI, ROS/MAP, IGAP, M2OVE-AD,
Resilience-AD, ACT) are being identified and engineered into
existing mouse genes under endogenous promoters (Karch and
Goate, 2015). As a heterogenous disease, it is unlikely that
a single genetic alteration will promote the complex set of
endophenotypes observed in humans. Rather, a combination of
genetic and/or environmental risk factors is likely needed to
phenocopy human disease and a better understanding of the
effects of the complex interrelationships between risk factors
is required to identify prospective therapeutic avenues. To this
end, new mouse strains and conditions better replicating human
LOAD are needed to improve the clinical translation of mouse
therapies in human patients.
To date, approximately 40 loci have been identified through
genetic and genome-wide association studies that increase the
risk for AD (Dourlen et al., 2019; Andrews et al., 2020; Bellenguez
et al., 2020). The strongest of these risk factors include the
ε4 allele of apolipoprotein E (APOE) and point mutations in
triggering receptor expressed on myeloid cells 2 (TREM2) locus
(Allen et al., 2016; Cacace et al., 2016; Wang et al., 2018; Logsdon
et al., 2019; Andrews et al., 2020; Bellenguez et al., 2020). These
mutations were characterized in C57BL/6J mice alone and each
correlated by gene-expression analysis to human transcripts to
predict risk. Furthermore, by expressing both risk alleles in
concert, genetic interaction and parallel molecular pathways
could be investigated for dominance or synergistic effects that
may promote human-like disease signatures.
APOE, the strongest genetic determinant of LOAD risk, has
been the focus of extensive investigation for many years (Bu,
2009; Arnold et al., 2020; Foley et al., 2020), including the
development of multiple mouse models expressing transgenes
or targeted mutations (Xu et al., 1996; Raber et al., 1998; Sun
et al., 1998; Knouff et al., 1999; Huber et al., 2000; Tesseur
et al., 2000; Lesuisse et al., 2001; Bien-Ly et al., 2012). APOE
is important in lipoprotein metabolism and immunoregulation
strongly associated with cardiovascular and Alzheimer’s disease
(Karch and Goate, 2015; Allen et al., 2016; Cacace et al., 2016;
Yamazaki et al., 2016; Wang et al., 2018; Logsdon et al., 2019;
Andrews et al., 2020; Bellenguez et al., 2020). Three isoforms of
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APOE are expressed in the human population:APOEε2,APOEε3,
and APOEε4 which confer increasing risk of LOAD, respectively.
Compared to APOEε3 carriers, the ε4 isoform of APOE increases
AD risk and decreases the age of diagnoses (Saunders et al.,
1993; Strittmatter et al., 1993). The three isoforms differ by one
amino acid each at positions 112 and 158 that has profound
effects on their functions: APOEε2 (Cys112, Cys158); APOEε3
(Cys112, Arg158); and APOEε4 (Arg112, Arg158). The APOE
protein has been shown to stimulate binding, transport, and
metabolism of lipoproteins, major cholesterol transporters in the
central nervous system (CNS) resulting in hypocholesteremia,
tight junction failure, and vascular dysregulation (Maezawa et al.,
2006c; Jeong et al., 2019). Additionally, reports of mice carrying
human APOEε4-targeted replacement allele show evidence of
blood-brain barrier (BBB) leakiness (Methia et al., 2001; Bell
et al., 2012), immune alterations (Laskowitz et al., 2000; Maezawa
et al., 2006a,b; Chung et al., 2016), synaptic disfunction (Safieh
et al., 2019), and behavior deficits (Wang et al., 2005). Most
importantly, APOE is also implicated in beta-amyloid and tau
clearance (Verghese et al., 2013; Shi et al., 2017). However, many
of the aspects of LOAD are not recapitulated upon expression of
APOEε4 alone, including the formation of beta-amyloid plaques
and neurofibrillary tangles (Wang et al., 2005).
TREM2 encodes a member of a receptor signaling complex
with TYRO protein tyrosine kinase binding (TYROBP) protein,
which activates microglia, macrophages, and dendritic cells
during damage and immune responses (Ma et al., 2015; Keren-
Shaul et al., 2017; Krasemann et al., 2017) functioning in
processes like debris clearance (Kleinberger et al., 2017) and
amyloid plaque response (Jay et al., 2015;Wang et al., 2015; Yuan
et al., 2016). Single nucleotide polymorphisms (SNP) found in
TREM2 have been shown to regulate microglial function (Painter
et al., 2015; Krasemann et al., 2017; Mazaheri et al., 2017), the
most widely studied being the R47H missense mutation in exon
2. The TREM2*R47H mutation triples the carrier’s likelihood
of Alzheimer’s disease (Allen et al., 2016; Cacace et al., 2016;
Wang et al., 2018; Logsdon et al., 2019; Andrews et al., 2020;
Bellenguez et al., 2020). The increased risk is suggested to
be, in part, the result of decreases in the microglial receptor’s
interactions with ligands (phospholipids, APOE, and beta-
amyloid) yielding chronic dysfunction inmicroglial phagocytosis
and inflammatory pathways (Karch and Goate, 2015; Ma et al.,
2015; Painter et al., 2015).
Here we describe the application of a multi-faceted, cross-
sectional phenotyping approach developed by MODEL-AD
that included biometrics, behavioral assays, transcriptomics,
neuroimaging, and immunohistochemistry to assess
AD-relevant phenotypes in mice expressing combinations
of humanized APOEε4 and Trem2*R47H alleles.
MATERIALS AND METHODS
Model Backgrounds
All animals were obtained from The Jackson Laboratory. Mouse
models of Late-onset Alzheimer’s disease (LOAD) developed by
MODEL-AD (Model OrganismDevelopment and Evaluation for
Late-onset Alzheimer’s Disease) are congenic to the C57BL/6J
(JAX# 000664; B6) strain. Genetic variants, identified from
human data compiled by the AMP-AD (Accelerating Medicines
Partnership-Alzheimer’s Disease) project, expressed in MODEL-
AD-generated strains are listed on the MODEL-AD strain table
at https://www.model-ad.org/strain-table/, along with relevant
links for allele descriptions, data, distribution, and legal
disclaimers.
B6J.APOE4.Trem2*R47H (LOAD1) Mice
The B6.APOE4.Trem2*R47H (LOAD1) double mutant strain
created at The Jackson Laboratory in Bar Harbor, Maine
carries two primary risk alleles found in Alzheimer’s disease
patients. The humanized ApoE knock-in allele, in which a
portion of the mouse Apoe gene (exons 2, 3, a majority of
exon 4, and some 3’ UTR sequence) of the mouse Apoe gene
was replaced by the corresponding sequence of the human
APOE4 gene (available as B6(SJL)-Apoetm1.1(APOE∗4)Adiuj/J1,
Foley et al., 2020). The second allele, Trem2, contains the
R47H point mutation and two additional silent mutations
(available as C57BL/6J-Trem2em1Adiuj/J2). The human R47H
variant, when expressed in mouse brains, also confers a novel
splice variant due to a cryptic slice acceptor site in exon 2
(Xiang et al., 2018). See additional information in the Jackson
Laboratory APOE4.Trem2R47H mouse (JAX strain #028709)
strain data sheet. APOE4.Trem2R47H mouse strain data sheet at
https://www.jax.org/strain/028709.
Experimental Cohorts
To decipher how these two strong risk factors drive
AD-relevant phenotypes, we created a double homozygous
B6.APOE4.Trem2*R47H model, accompanied by single
genotype controls, on a C57BL/6J (B6) background (Table 1).
In appreciation of sexual dimorphism observed in human aging
and disease, cohorts of males and females were established for
phenotyping at 4-, 8-, 12- and 24-months using a cross-sectional
design. To determine whether the LOAD risk variants APOEε4,
Trem2*R47H, or the combination produced in vivo phenotypes
independent from normal healthy aging, a comprehensive
cross-sectional phenotyping battery was conducted and included
in vivo frailty assessments, metabolic screening, microbiome
sampling, biomarker evaluation, behavioral phenotyping, and
in vivo imaging. Postmortem brain tissue was further examined
for transcriptomic and neuropathological indications of disease.
All accumulated data sets and observations are disseminated for
public availability (Kotredes, 2020).
Animal Housing Conditions
All experiments were approved by the Animal Care and Use
Committee at The Jackson Laboratory and the Institutional
Animal Care and Use Committee at Indiana University. To
minimize gene expression variation between mice, animal
housing conditions were replicated between both Bar Harbor and
Indianapolis campuses. Mice were bred in the mouse facility at
Indiana University or The Jackson Laboratory and maintained
1https://www.jax.org/strain/027894
2https://www.jax.org/strain/027918
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in a 12/12-h light/dark cycle, consisting of 12 h-ON 7 am-
7 pm, followed by 12 h-OFF. Room temperatures are maintained
at 18–24◦C (65–75◦F) with 40–60% humidity. All mice were
housed in positive, individually ventilated cages (PIV). Standard
autoclaved 6% fat diet (Purina Lab Diet 5K52) was available
to the mice ad-lib, as was water with acidity regulated from
pH 2.5–3.0. All breeder and experimental mice were housed in
the same mouse room and were aged together. All behavioral
characterization was conducted in the Mouse Neurobehavioral
Core Facility (MNBF) at The Jackson Laboratory. Briefly, mice
were relocated from the housing room in which they were
reared to the MNBF in an adjacent building on the Bar Harbor
campus. Mice were individually housed at minimum 5 days
prior to behavioral testing. The dedicated MNBF housing room
consists of PIV caging with temperature controlled at a setting
of 22 ± 1◦C (72 ± 2◦F) and hsumidity at 50 ± 20%. The
testing facility was on a 12:12 L:D schedule (lights on at 6:00
am) with all testing performed during the light cycle (typically
between 7:00 am and 5:00 pm, with the exception of wheel
running which was continuous 24-h testing for up to 5 days). All
subjects were randomized and counterbalanced for testing order
across multiples of instrumentation and time of day for each test
day, with a simplified testing ID number (e.g., #1-100), with all
technicians blinded to genotype (e.g., coded as A, B, C, etc.). The
blind was maintained throughout testing and until after the data
were analyzed with no subjects or data excluded based on any
mathematical outliers.
Behavioral Testing
Behavioral tests were conducted as previously reported (Sukoff
Rizzo et al., 2018) in the following order with at minimum a 1–2-
day rest period between tests: Frailty assessment with core body
temperature recording, open field test, spontaneous alternation,
rotarod, and wheel-running activity. On each test day, subjects
were transported from the adjacent housing room into the
procedure room, tails were labeled with a non-toxic permanent
marker with the assigned subject ID number, and subjects were
left to acclimate undisturbed to the testing environment for a
minimum 60 min prior to testing. Between subjects, all testing
arenas were sanitized with 70% ethanol solution and dried prior
to introducing the next subject. Lighting in the testing rooms
were consistent with the housing room (∼500 lux) unless where
specifically noted. At minimum 5 days post the conclusion of
behavioral testing, mice were sent for tissue harvesting.
Frailty Assessment
Similar to as previously described (53), subjects were individually
evaluated for the absence or presence of 26 aging-related
characteristic traits and scored a 0, 0.5, or 1 (based on
presence/absence, and severity) for each assessment by a
trained observer, blind to genotype/age, and included the
following assessments: alopecia; loss of fur color; dermatitis/skin
lesions; loss of whiskers; coat condition; piloerection; cataracts;
eye discharge/swelling; microphthalmia; nasal discharge;
rectal prolapse; vaginal/uterine/penile; diarrhea; vestibular
disturbance; vision loss assessed by visual placing upon the
subject being lowered to a grid; menace reflex; tail stiffening;
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impaired gait during free walking; tremor; tumors; distended
abdomen; kyphosis; body condition; breathing rate/depth;
malocclusions; righting reflex. The frailty index score was
calculated as the cumulative score of all measures with a
maximum score of 26.
Core Body Temperature
Core body temperature was recorded just prior to the conclusion
of the frailty assessment via a glycerol lubricated thermistor
rectal probe (Braintree Scientific product# RET 3; measuring
3/4" L 0.028 dia. 0.065 tip) inserted ∼2 cm into the rectum
of a manually restrained mouse for approximately 10 s. The
temperature was recorded to the nearest 0.1◦C (Braintree
Scientific product#TH5 Thermalert digital thermometer).
Open Field Activity
Versamax Open Field Arenas (40 cm × 40 cm × 40 cm;
Omnitech Electronics, OH, USA) were used for this test. Arenas
were housed within sound-attenuated chambers with lighting in
the testing room and arenas consistent with the housing room
(∼500 lux). Mice were placed individually into the center of
the arena and infrared beams recorded distance traveled (cm),
vertical activity, and perimeter/center time. Data were collected
in 5-min time-bins for a duration of 60 min.
Spontaneous Alternation
Mice were acclimated to the testing room under ambient lighting
conditions (∼50 lux). A clear polycarbonate y-maze (in-house
fabricated; arm dimensions 33.65 cm length, 6 cm width, 15 cm
height) placed on top of an infrared reflecting background
(Noldus, The Netherlands), surrounded by a black floor-to-
ceiling curtain to minimize extramaze visual cues was used for
this test. Mice were placed midway of the start arm (A), facing
the center of the y for an 8-min test period and the sequence of
entries into each arm is recorded via a ceiling-mounted infrared
camera integrated with behavioral tracking software (Noldus
Ethovision XT). Percent spontaneous alternation is calculated
as the number of triads (entries into each of the three different
arms of the maze in a sequence of three without returning to
a previously visited arm) relative to the number of alteration
opportunities.
Rotarod Test for Motor Coordination
An accelerating Rotarod (Ugo-Basile; model 47600) is used for
this test. Lighting in the testing room is consistent with the
housing room (∼500 lux). The trial began with mice being
placed on the rotating rod (4 rpm), which accelerates up to
40 rpm over the course of 300 s. Each mouse is subjected
to three consecutive trials with an ∼1 min inter-trial interval
to allow cleaning of the rod between trials. Latency to fall
(sec) is measured. Subjects that fall upon initial placement on
the rod, before acceleration begins, are scored as 0 s for that
trial.
Wheel Running Activity
Subjects were individually housed in a clean cage with a running
wheel (Med-Associates, Vermont, USA) and with food and water
ad libitum. The light cycle was identical to the housing roomwith
12:12 L:D (lights on at 6:00 am). Running wheels were equipped
with a wireless transponder that recorded activity on the running
wheels (revolutions) in sync with a computer that time stamps
events. Mice were left undisturbed throughout the testing period
with the exception of daily welfare checks. Data were evaluated
for time spent running (min), total distance traveled (meters),
and speed (revolutions per min) over the course of three 24-h
periods.
Behavioral Data Analysis
Prior to data analysis and while still blinded, results were adjusted
to exclude data only from mice which could not be tested
or which data was not available inclusive of any equipment
failures, escape episodes, etc. Subjects were not excluded by any
mathematical determination. Data were analyzed under coded
genotypes (A, B, C, etc.) within sex, as one-way or two-way
ANOVA as appropriate vs. sex- and age- matched WT control.
The blind was revealed at the conclusion of the data analysis for
interpretation.
Fasting Blood Glucose Collection and
Measurement
Fasted mice were placed into a fresh cage, free of food but with
fresh water, at 6 am—the beginning of the light-ON cycle. Mice
were made to fast for 6 h, until 12 pm, at which time blood
glucose levels were analyzed. Prior to mouse restraint, a Contour
Next EZ blood glucose monitor (Ascensia, Parsippany, NJ) was
calibrated with Contour glucose control solution and Contour
Next test strips. While restraining the animal, with a 5.0 mm
lancet a stab incision was made into and perpendicular to the
cheek, located dorsal to the cheek skin gland at a distance equal
to the height of the eye and caudal distance equal to the length of
the eye. One drop of blood, approximately 10 µl, was applied to
a blood glucose test strip and readings were recorded.
Fecal Collection
Parallel with the measurement of animal weight, animals were
placed in a clean container on a scale. Mouse weight was recorded
and upon production, a fecal sample was collected with forceps to
prevent contamination. The sample was placed in a pre-marked
1.5 ml tube and snap-frozen immediately on dry ice. Container
and forceps were cleanedwith 70% ethanol before collecting from
subsequent mice. Fecal samples were stored long term at −80◦C
until analyzed.
Animal Anesthesia
Upon arrival at the terminal endpoint for each aged mouse
cohort, individual animals were weighed prior to intraperitoneal
administration of either: (A) ketamine (100 mg/kg) and
xylazine (10 mg/kg); or (B) tribromoethanol (1 mg/kg). Routine
confirmation of deep anesthesia was performed every 5 min by
toe pinch. First confirming deep anesthetization via toe pinch,
an incision along the ventral midline to expose the thorax and
abdomen, followed by removal of the lateral borders of the
diaphragm and ribcage revealed the heart. If desired, prior to
perfusion blood and CSF samples must be collected. To perfuse
the animal, a small cut was placed in the right atrium to relieve
pressure from the vascular system before perfusing the animal
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transcardially with 1× PBS via injection into the left ventricle.
Completion of perfusion and clearance of the vascular system
was indicated by blanching of the liver.
Whole Animal Perfusion
First confirming deep anesthetization via toe pinch, animals are
secured to a surgical board or tray using needles or pins and
abdomen wetted with 70% ethanol followed by an incision along
the ventral midline along the entire ventral surface, exposing the
underlying muscle of the thorax and abdomen. An additional
incision is made into this underlying muscle and cut to puncture
the diaphragm, taking care not to cut any major blood vessels
or the lungs. To expose the heart the ribcage can be cut along the
lateral borders and removed. A small incision is made in the right
atrium of the heart to relieve diastolic pressure and begin the
removal of blood from the vascular system. To clear the vascular
system of all blood a butterfly catheter needle is inserted into the
left ventricle attached to a perfusion pump. Approximately 10 ml
of 1× PBS solution will clear the system of a 20 g animal. Once
the system has been cleared of blood the liver will appear very
pale and PBS will be noticed exiting the right atrium. At this time
organs of interest were collected as indicated.
Non-fasting Blood Collection and Analysis
Blood was collected by cardiac puncture from non-fasted,
anesthetized animals (see Perfusion method) at harvest prior
to incision of the right atrium and subsequent perfusion. A
25-gauge EDTA-coated needle, attached to a 1 ml syringe, is
inserted into the right atrium of the exposed heart and the
plunger gently pulled to slowly aspirate approximately 500 ml
of blood, avoiding entrapping air in the syringe to prevent
hemolysis. After removal of the needle from the syringe, the
blood was slowly injected into a 1.5 ml EDTA coated MAP-K2
bloodmicrotainer (363706, BD, San Jose, CA) on ice. Blood tubes
were spun at 4◦C and 4,388× g for 15 min. Blood serum is
then removed and aliquoted equally into three replicate 1.5 ml
tubes on ice. Tubes were then snap-frozen on dry ice and
stored long-term at −80◦C. Thawed blood plasma collected
from non-fasted mice was then analyzed by Beckman Coulter
AU680 chemistry analyzer (Beckman Coulter, Brea, CA) and
Siemens Advia 120 (Germany) for levels of non-fasted glucose,
total cholesterol, LDL (low-density lipoproteins), HDL (high-
density lipoproteins), triglycerides, and NEFA (non-essential
fatty acids).
Brain Harvest
Anesthetized and subsequently perfused animals were
decapitated, and heads submerged quickly in cold 1× PBS.
The brain was carefully removed from the skull, weighed, and
divided midsagitally, into left and right hemispheres, using a
brain matrix. The right hemisphere was quickly homogenized on
ice and equally aliquoted into three cryotubes for metabolomic,
proteomic, and transcriptomic analysis. Cryotubes were
immediately snap-frozen on dry ice and stored long-term at
−80◦C. The left hemisphere was immediately placed in 5 ml 4%
PFA at 4◦C for no less than 24 h, but no longer than 30 h. The
left hemisphere was then moved from PFA solution to 10 ml
15% sucrose at 4◦C for 24 h, or until it sinks in the sucrose, when
it was then transferred to a 30% sucrose for 24 h at 4◦C, or until
it sinks in the solution. The left hemisphere was then removed
from 30% sucrose solution, snap-frozen on a flat mold, cut-side
down, floating in 2-methyl butane solution cooled by dry ice.
Once frozen the left hemisphere is then placed into a cryotube




During harvest, whole mouse brains were removed and
weighed. Using a brain matrix, left and right hemispheres were
separated along the midsagittal plane. The left hemisphere was
placed in 5 ml of 4% PFA at 4◦C overnight, then moved to
10 ml of 15% sucrose at 4◦C overnight, before finally being
incubated in 10 ml of 30% sucrose at 4◦C overnight or until
the brain sinks to the bottom of the tube. The left hemisphere
was then snap-frozen and stored at −80◦C until sectioned.
Left hemispheres (see preparation in Brain harvest method)
were cut via Thermo Scientific HM430 sliding microtome at
25 µm thickness. Coronal brain tissue sections were oriented
to capture the cortex and hippocampus at approximately
Bregma: −2.75 mm and Interaural 1.05 mm. Each section
was placed into cryoprotectant buffer (37.5% 1× PBS, 31.25%
glycerol, 31.25% ethylene glycol) for immediate use or long-term
storage at −20◦C. Each section was tracked so as to store
100 sections equally distributed over 10 groups, so each of the
10 groups had equal representation of the 10 sections from
the forebrain to the hindbrain and the hippocampus. Of these
10 groups of 10 25-micron sections, seven will be used for
standardized staining combinations highlighting cell types and
markers of interest: (1) Vascular [CD31/Iba1/Fibrin/DAPI];
(2) Neuritic plaques [Lamp1/Iba1/X34]; (3) Astrocytes
and microglia [GFAP/Iba1/S100b/DAPI]; (4) Neurons
[NeuN/Ctip2/DAPI]; (5) Plaques [ThioS]; (6) Luxol Fast
Blue/Cresyl Violet; (7) Haematoxylin and eosin; and (8) Prussian
blue (Iron stain). Floating sections were then blocked prior to
immunohistochemical staining and mounting. After blocking
slides with 10% normal donkey serum or normal goat serum
diluted in 1× PBS+0.5%Triton wash buffer all antibodies were
washed floating in 1× PBT (1× PBS with 0.5% Triton) wash
buffer after blocking for 1 h at room temperature on a shaker
in 10% NGS (normal goat serum) or 10% NDS (normal donkey
serum) in 1× PBT. Secondary antibodies were incubated in
10% NGS or NDS in 1× PBT for 1 h at room temperature,
followed by washes in 1× PBT before mounting onto the slides.
Each staining combination of 10 sections was placed onto one
slide. DAPI, X34, and ThioS stains were performed on the slide
following immunostaining. Slides were then imaged on a Leica
Versa slide scanner, automated fluorescent microscope system
(Leica, Allendale, NJ). For further analysis, regions of the cortex
and hippocampus were processed using CellProfiler (Cambridge,
MA) or Imaris (Bitplane, Concord, MA) software to quantify cell
counts, fluorescence intensity, and surface area ratios. [CD31
(R&D Systems, MAB3628, 1:500), Iba1 (Wako, 019-19741,
1:300), Fibrin (abcam, ab118533, 1:500), DAPI (1:1,000), Lamp1
(abcam, ab25245, 1:500), X34 (0.04% in 40% ethanol), GFAP
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(Origene, AP31806PU-N, 1:1,000), S100b (Thermo Fisher,
PA175395, 1:1,000), NeuN (abcam, ab104225, 1:500), Ctip2
(abcam, ab18465, 1:1,000), and ThioS (1% in 50% ethanol)].
In vivo Imaging Radiopharmaceuticals and
Study Population
Regional brain glycolytic metabolism was monitored using
2-[18F]-fluoro-2-deoxy-D-glucose (18F-FDG) and was
synthesized, purified, and prepared according to established
methods (Yu et al., 2006), where clinical unit doses ranging from
185–370 MBq (5–10 mCi) were purchased from PETNet Indiana
(PETNET Solutions Inc). To evaluate region brain perfusion,
Copper(II) pyruvaldehyde bis(N4-methylthiosemicarbazone)
labeled with 64Cu (64Cu-PTSM) was synthesized, purified,
and unit doses (i.e., 370–740 MBq (10–25 mCi)) dispensed by
the PET Radiochemistry Core Facility at Indiana University
according to methods described previously (Green, 1987;
Mathias et al., 1990).
Magnetic Resonance Imaging (MRI)
To provide high contrast gray matter images, at least 2
days prior to PET imaging, mice were induced with 5%
isoflurane (balance medical oxygen), placed on the head coil,
and anesthesia maintained with 1–3% isoflurane for scan
duration. High-resolution T2-weighted (T2W)MRI images were
acquired using a 3T Siemens Prisma clinical MRI scanner
outfitted with a dedicated 4 channel mouse head coil and
bed system (RapidMR, Columbus OH). Images were acquired
using a SPACE3D sequence (Algin and Ozmen, 2012) using the
following acquisition parameters: TA: 5.5 min; TR: 2,080 ms;
TE: 162 ms; ETL: 57; FS: On; Ave: 2; Excitation Flip Angle: 150;
Norm Filter: On; Restore Magnetization: On; Slice Thickness
0.2 mm: Matrix: 171 × 192; FOV: 35 × 35 mm, yielding
0.18× 0.18× 0.2mm resolution images. At the completion of the
imaging period, mice we returned to their warmed home cages
and were allowed to recover.
Positron Emission Tomography (PET)
Imaging
To evaluate changes in cerebral glycolysis (18F-FDG) and
cerebral perfusion (64Cu-PTSM)mice were placed in a restrainer
and consciously injected into the peritoneal or tail vein,
respectively, with 3.7–11.1 MBq (0.1–0.3 mCi) of purified,
sterile radiotracer, where the final volume did not exceed 10%
of the animal’s body weight. Each animal was returned to
its warmed home cage and allowed 30 min (18F-FDG) or
5 min (64Cu-PTSM) to allow for uptake and cellular trapping
(Sokoloff, 1977; Mathias et al., 1991a). Post-uptake, mice were
induced with 5% isoflurane gas, placed on the scanner imaging
bed, and anesthesia maintained at 1–3% isoflurane (balance
medical oxygen) during acquisition. In all cases, calibrated PET
acquisition was performed in list mode for 15 (18F-FDG) or
30 (64Cu-PTSM) min on an IndyPET3 scanner (Frese et al.,
2003), where random prompts did not exceed 10% of the total
prompt rate. Post-acquisition, the images were reconstructed
into a single-static image with a minimum field of view of
60 mm using filtered-back-projection (FBP), and were corrected
for decay, random coincidence events, and dead-time loss (Soon
et al., 2007).
In vivo PET/CT Imaging
To assess regional glycolysis and tissue perfusion,
mice will be non-invasively imaged via PET/CT
(n = 10 mice/sex/genotype/age). To measure regional blood
flow, copper-pyruvaldehyde-bis (N4-methylthiosemicarbazone;
64Cu-PTSM; Green, 1987), which has a very high first pass
(>75%) extraction (Mathias et al., 1991b), and glutathione
reductase redox trapping of copper (Mathias et al., 1991b),
will be administered via tail vein in awake subjects and will
be given a 2 min uptake period prior to imaging. To measure
regional glycolytic metabolism, 2-fluoro-2-deoxyglucose (18F-
FDG) will be administered via tail vein in awake subjects and
mice will be given a 30 min uptake period prior to imaging.
Post uptake, mice will be induced with 5% isoflurane (95%
medical oxygen) and maintained during acquisition with 1–2%
isoflurane at 37◦C. To provide both anatomical structure and
function, PET/CT imaging will be performed with a Molecubes
β-X-CUBE system (Molecubes NV, Gent Belgium). For PET
determination of blood flow andmetabolism, calibrated listmode
PET images will be acquired on the β-CUBE and reconstructed
into a single-static image using ordered subset expectation
maximization (OSEM) with 30 iterations and three subsets
(Krishnamoorthy et al., 2018). To provide anatomical reference,
and attenuation maps necessary to obtain fully corrected
quantitative PET images, helical CT images were acquired
with tube voltage of 50 kV, 100 mA, 100µm slice thickness,
75ms exposure, and 100µm resolution. In all cases, images
will be corrected for radionuclide decay, tissue attenuation,
detector dead-time loss, and photon scatter according to the
manufacturer’s methods (Krishnamoorthy et al., 2018). Post-
acquisition, all PET and CT images will be co-registered using
a mutual information-based normalized entropy algorithm
(Studholme et al., 1998) with 12 degrees of freedom and mapped
to stereotactic mouse brain coordinates (Paxinos and Franklin,
2012). Finally, to quantify regional changes, voxels of interest
(VOI) for 27 brain (54 bilateral) regions will be extracted
and analyzed for SUVR according to published methods
(Dandekar et al., 2007).
Autoradiography
To provide secondary confirmation of the in vivo PET images,
and to quantify tracer uptake regionally, brains were extracted
post rapid decapitation, gross sectioned along the midline, slowly
frozen on dry ice, then embedded in cryomolds with Optimal
Cutting Temperature (OCT) compound (Tissue-Tek). Thin
frozen sections (20 um) were obtained via cryotomy at prescribed
bregma targets (n = 6 bregma/mouse, 6 replicates/bregma)
according to stereotactic mouse brain coordinates (Franklin and
Paxinos, 2013). Sections were mounted on glass slides, air dried,
and exposed on BAS Storage Phosphor Screens (SR 2040 E,
Cytiva Inc.) for up to 12 h. Post-exposure, screens were imaged
via Typhoon FL 7000IP (GE Medical Systems) phosphor-imager
at 25 um resolution along with custom 18F or 64Cu standards
described previously (Territo et al., 2017).
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Image Analysis
All PET and MRI images were co-registered using a ridged-body
mutual information-based normalized entropy algorithm
(Studholme et al., 1997) with 9 degrees of freedom, and mapped
to stereotactic mouse brain coordinates (Franklin and Paxinos,
2013) using Analyze 12 (AnalyzeDirect, Stilwell KS). Post-
registration, 56 regions bilateral regions were extracted via
brain atlas and averaged to yield 27 unique volumes of interest
that map to key cognitive and motor centers that include:
Agranular Insular Cortex; Auditory Cortex; Caudate Putamen,
Cerebellum; Cingulate Cortex; Corpus Callosum; Dorsolateral
Orbital Cortex; Dorsintermed Entorhinal Cortex; Dysgranular
Insular Cortex; Ectorhinal Cortex; Fornix; Frontal Association
Cortex; Hippocampus; Lateral Orbital Cortex; Medial Orbital
Cortex; Parietal Cortex; Parietal Association Cortex; Perirhinal
Cortex; Prelimbic Cortex; Primary Motor Cortex; Primary
Somatosensory Cortex; Retrosplenial Dysgranular Cortex;
Secondary Motor Cortex; Secondary Somatosensory Cortex;
Temporal Association Cortex, Thalamus; Ventral Orbital
Cortex; Visual Cortex. For autoradiographic analysis,
tracer uptake was quantified on hemi-coronal sections by
manually drawing regions of interest for 17 regions of interest
(i.e., Auditory Cortex, Caudate Putamen, Cerebellum, Cingulate
Cortex, Corpus Callosum, Dorso-intermed Entorhinal Cortex,
Dysgranular Insular Cortex, Ectorhinal Cortex, Hippocampus,
Hypothalamus, Medial Septum, Primary Motor Cortex, Primary
Somatosensory Cortex, Retrosplenial Dysgranular Cortex,
Temporal Association Cortex, Thalamus, Visual Cortex)
on calibrated phosphor screen at bregma 0.38, −1.94, and
−3.8 mm using MCID (InterFocus Ltd). To permit dose and
brain uptake normalization, Standardized Uptake Value Ratios
(SUVR) relative to the cerebellum were computed for PET and
autoradiograms for each subject, genotype, and age as follows:
SUVR(s,R, g, a) =
R(s, g, a)
C(s, g, a)
where, s, g, a, R, and C are the subject, genotype, age,
region/volume of interest, cerebellum region/volume of interest.
In all cases, region/volumes of interest were analyzed for
differences with time and genotype using a Two-Way ANOVA
(Prism, GraphPad Inc.), where significance was taken at p< 0.05.
Immunoprecipitation
Tissue samples were homogenized in tissue protein extraction
reagent (T-PER ThermoScientific) supplemented with protease
and phosphatase inhibitors cocktail (Sigma-Aldrich). Protein
concentration was measured using bicinchoninic acid (BCA;
Pierce). Immunoprecipitation was performed by incubating a
total of 1,500µg of brain protein extract with 1µg of biotinylated
sheep anti-Trem2 antibody (RnD systems BAF1729) overnight
at 4◦C, followed by incubation with streptavidin sepharose beads
(CST 3419) for 6 h at 4◦C, washed three times with ice cold PBS
with 0.1% Tween 20. Protein was eluted in sample loading buffer
with 1 mM DTT followed by separation via Western blot (see
below).
Western Immunoblot
Snap-frozen right hemispheres were homogenized by hard tissue
homogenizer (USA Scientific, Ocala, FL) and lysed in 1 ml
RIPA buffer (R0278, Sigma, St. Louis, MO) supplemented with
protease and phosphatase inhibitor reagents (1861281, Thermo
Fisher Scientific, Waltham, MA). Lysates were incubated for
1 h at 4◦C before pelleting insoluble proteins by spinning
at 4◦C, 11,000× g for 15 min. Protein concentration was
determined by Bradford protein assay (Biorad, Hercules,
CA), according to the manufacturer’s instructions. Samples
were mixed with 10× Laemlli buffer (42556.01, Amsbio,
Cambridge, MA), boiled for 10 min, and run on 12% SDS
PAGE gels (456-1044, BioRad) with a colorimetric ladder
(RPN800E, GE, Boston, MA). Gels were transferred to PVDF
membranes for immunoblotting and imaging using an iBlot2 dry
blotting system (Thermo Fisher). Membranes were blocked
in 5% non-fat dry milk in 1× PBS+0.1% Tween20 for 1 h
prior to incubating with primary antibodies diluted in 5%
non-fat dry milk in 1× PBS+0.1% Tween20 for 1 h at
room temperature. Membranes were washed in 1× PBS+0.1%
Tween20 before incubating with secondary antibodies diluted in
5% non-fat dry milk in 1× PBS+0.1% Tween20. HRP-conjugated
secondary antibodies targeting primary antibody host IgG
were incubated at 1 h at room temperature. Membranes
were washed in 1× PBS+0.1% Tween20 before digital imaging
with SuperSignal West Pico PLUS chemiluminescent substrate
(34579, Thermo Fisher). Images for immunoblot were quantified
using ImageJ 1.8.0 version. Proteins of interest were visualized
with the following primary antibodies against: ACTIN (Abcam,
ab179467), GAPDH (abcam, ab9483), APOE4 (Novus, NBP1-
49529), TREM2 (R&D Systems, MAB1729), and Alpha-tubulin
(Sigma-Aldrich, T9026-100UL).
Cytokine Panel Assay
Hemibrains were homogenized in tissue homogenization buffer
containing fresh protease inhibitor cocktail and aliquoted. The
supernatant was utilized for the cytokine analysis. Mouse
hemibrain samples were assayed in duplicate using the MSD
mouse proinflammatory Panel I, a highly sensitive multiplex
enzyme-linked immunosorbent assay (ELISA). The panel
quantifies 10 cytokines: interferon gamma (IFN-γ), interleukin
(IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and tumor
necrosis factor α (TNFα) from a single small sample volume
(25 µl) using an electrochemiluminescent detection method
(MesoScale Discovery, Gaithersburg, MD, USA). The mean
intra-assay coefficient for each cytokine was <8.5%, based on
cytokine standards. Any value that was below the lowest limit
of detection (LLOD) for the cytokine assay was replaced with 12
LLOD of the assay for statistical analysis.
RNA-Sequencing Experimental Design
RNA-Seq data were obtained from whole left hemisphere brain
samples from APOE4 KI mouse, carrying a humanized version
of the prominent APOEε4 genetic risk factor for LOAD, and the
Trem2*R47H mouse, carrying a rare deleterious variant R47H
allele of Trem2 gene. In addition, a mouse model expressing
both human APOEε4 and the Trem2*R47H mutation was used
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to compare the transcriptional changes in mice carrying both
variants to mice carrying only a single risk allele and B6 controls.
Whole-brain left hemispheres were collected at 4, 8, 12, and
24 months of age from both sexes.
RNA Sample Extraction
Total RNA was extracted from snap-frozen right brain
hemispheres using Trizol (Invitrogen, Carlsbad, CA). mRNA
was purified from total RNA using biotin-tagged poly dT
oligonucleotides and streptavidin-coated magnetic beads
and quality was assessed using an Agilent Technologies
2100 Bioanalyzer (Agilent, Santa Clara, CA).
RNA-Sequencing Assay Library
Preparation
Sequencing libraries were constructed using TruSeq DNA V2
(Illumina, San Diego, CA) sample prep kits and quantified
using qPCR (Kapa Biosystems, Wilmington, MA). The mRNA
was fragmented, and double-stranded cDNA was generated
by random priming. The ends of the fragmented DNA were
converted into phosphorylated blunt ends. An ‘‘A’’ base was
added to the 3’ ends. Illuminar-specific adaptors were ligated to
the DNA fragments. Using magnetic bead technology, the ligated
fragments were size-selected and then a final PCR was performed
to enrich the adapter-modified DNA fragments since only the
DNA fragments with adaptors at both ends will amplify.
RNA-Sequencing
Libraries were pooled and sequenced by the Genome
Technologies core facility at The Jackson Laboratory. All
samples were sequenced on Illumina HiSeq 4000 using HiSeq
3000/4000 SBS Kit reagents (Illumina), targeting 30 million read
pairs per sample. Samples were split across multiple lanes when
being run on the Illumina HiSeq, once the data was received the
samples were concatenated to have a single file for paired-end
analysis.
RNA-Sequencing Data Processing
Sequence quality of reads was assessed using FastQC (v0.11.3,
Babraham). Low-quality bases were trimmed from sequencing
reads using Trimmomatic (v0.33; Bolger et al., 2014). After
trimming, reads of length longer than 36 bases were retained.
The average quality score was greater than 30 at each base
position and sequencing depth was in range of 60–80 million
reads. RNA-Seq sequencing reads from all samples were mapped
to the mouse genome (version GRCm38.p6) using ultrafast
RNA-Seq aligner STAR (v2.5.3; Dobin et al., 2013). To measure
human APOE gene expression, we created a chimeric mouse
genome by concatenating the human APOE gene sequence
(human chromosome 19:44905754-44909393) into the mouse
genome (GRCm38.p6) as a separate chromosome (referred to
as chromosome 21 in chimeric mouse genome). Subsequently,
we added gene annotation of the human APOE gene into
the mouse gene annotation file. Additionally, we have also
introduced annotation for novel Trem2 isoform in mouse gene
annotation file (GTF file), that is identical to primary transcript
but truncated exon2 by 119 bp from its start position. Afterward,
a STAR index was built for this chimericmouse genome sequence
for alignment, then STAR aligner output coordinate-sorted BAM
files for each sample mapped to the chimeric mouse genome
using this index. Gene expression was quantified in two ways,
to enable multiple analytical methods: transcripts per million
(TPM) using RSEM (v1.2.31; Li and Dewey, 2011), and raw read
counts using HTSeq-count (v0.8.0; Anders et al., 2015).
Differential Expression Analysis
Differential expression in mouse models was assessed using
the R Bioconductor package DESeq2 (v1.16.1; Love et al.,
2014). DESeq2 takes raw read counts obtained from HTSeq-
count as input. Genes with the Benjamini-Hochberg corrected
p-values < 0.05 were considered as significantly differentially
expressed genes.
Principal Component Analysis
We analyzed a total of 234 RNA-Seq samples originating
from different mouse models of different ages and sex. First,
the dispersion parameter for each gene was estimated using
DESeq2 R package (Love et al., 2014). Afterward, we applied
the variance stabilizing transformation (vst) function of DESeq2
(Love et al., 2014) to the read count data in order to produce
a data matrix in which expression levels are homoscedastic.
Finally, we extracted the principal components using the plot
PCA function of DESeq2 in R.
Functional Enrichment Analysis
Functional annotations and enrichment analyses were performed
using the R Bioconductor package clusterProfiler (Yu et al.,
2012), with Gene Ontology terms and KEGG pathways
enrichment analyses performed using functions enrichGO and
enrichKEGG, respectively. The function compareCluster was
used to compare enriched functional categories of each gene
module. The significance threshold for all enrichment analyses
was set to 0.05 using Benjamini-Hochberg adjusted p-values.
Human Post-mortem Brain Cohorts and
Co-expression Module Identification
Whole-transcriptome data for human post-mortem brain tissue
was obtained from the Accelerating Medicines Partnership for
Alzheimer Disease-(AMP-AD) consortium, which is a multi-
cohort effort to harmonize genomics data from human LOAD
patients. Harmonized co-expression modules from the AMP-AD
data sets were obtained from the AD Knowledge Portal (DOI:
10.7303/syn11932957.1). The human co-expression modules
derive from three independent LOAD cohorts, including
700 samples from the ROS/MAP cohort, 300 samples from
the Mount Sinai Brain bank, and 270 samples from the Mayo
cohort. A detailed description of post-mortem brain sample
collection, tissue and RNA preparation, sequencing, and sample
QC has been provided elsewhere (Allen et al., 2016; De Jager
et al., 2018; Wang et al., 2018). As part of a transcriptome-wide
meta-analysis to decipher the molecular architecture of LOAD,
30 co-expression modules from seven different brain regions
across the three cohorts have been recently identified (Logsdon
et al., 2019). Briefly, Logsdon et al. (2019) identified 2,978
co-expression modules using multiple techniques across the
different regions after adjusting for co-variables and accounting
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for batch effects (10.7303/syn10309369.1). A total of 660
co-expression modules were selected based on a specific
enrichment in LOAD cases when compared to controls
(10.7303/syn11914606). Finally, multiple co-expression module
algorithms were used to identify a set of 30 aggregate modules
that were replicated by the independent methods (Logsdon et al.,
2019).
Mouse-Human Correlation Analysis
First, we performed differential gene expression analysis for each
mouse model compared to age and sex-matched B6 control mice
using the limma (Ritchie et al., 2015) package in R. Afterward,
we computed the correlation between changes in expression (log
fold change) for all DE genes in a given module with the fold
changes for each mouse model (specified by genotype, sex, diet,
and age). Correlation coefficients were computed using cor.test
function in R as:
cor.test(LogFC(h), LogFC(m)) (1)
where LogFC(h) is the log fold change in transcript expression of
human AD patients compared to control patients and LogFC(m)
is the log fold change in expression of mouse transcripts
compared to control mouse models. LogFC values for human
transcripts were obtained via the AD Knowledge Portal3.
Statistical Analysis
Statistical analyses were constrained to comparisons
between littermate-controlled subjects only
(B6.APOE4 v.B6.APOE4.Trem2*R47H). The student’s t-test
was employed on data sets differing by a single variable (e.g., age,
sex, genotype). ANOVA was used in data sets where multiple
factors are considered and combined for possible synergistic
effects.
Availability of Data and Materials
The LOAD1 data sets are available via the AD Knowledge
Portal4. The AD Knowledge Portal is a platform for accessing
data, analyses, and tools generated by the AcceleratingMedicines
Partnership (AMP-AD) Target Discovery Program and other
National Institute on Aging (NIA)-supported programs to enable
open-science practices and accelerate translational learning. The
data, analyses, and tools are shared early in the research cycle
without a publication embargo on a secondary use. Data is
available for general research use according to the following
requirements for data access and data attribution5.
For access to content described in this manuscript see:
https://doi.org/10.7303/syn23631984.
RESULTS
Biometric Profiles of APOE4.Trem2*R47H
Mice Change With Age
Comparison of biometric data from young (4 months) and aged




(Table 2), revealed the expected age-related accumulation in
physical frailty characteristics (Figures 1A,B) with inverse
correlations in body temperature (Supplementary Figure 1)
and age-related increases in body weights (Figures 1C,D).
However, effects due to genotype were not observed overall
(see also Supplementary Table 1). Statistical analyses were
constrained to contrasting only cohorts sharing littermates.
Effects of age and genotype on variability were observed
in datasets, as well as effective interaction, determined by
ANOVA. These results confirm a strong aging effect in all
assays. To determine the effects of APOEε4 and Trem2*R47H
on mouse metabolome, terminal non-fasted blood plasma
levels of metabolites were measured. Homozygous expression
of humanized APOEε4 resulted in a significant decrease of
non-fasted serum low-density lipoproteins (LDL) in the absence
of corresponding decreases in total cholesterol (Figures 1E–H).
Expected aging-specific-effects included decreases in glucose
and triglyceride levels in both sexes independent of genotypes
(Figures 1I–L). Other measurements and metabolic analytes
included in our panel were unchanged between sex, age,
and genotype cohorts (Supplementary Figures 1C–F and
Supplementary Table 2). Additional cohorts, investigating
APOEε4 allele alone compared with littermate B6 controls,
were aged to 12 months. Consistent with initial aging-related
phenotypes in the 4- and 24-month cohorts, there was an
expected increase in cumulative frailty scores, reductions in core
body temperature, and increase in body weight in both sexes
with no genotype-driven differences observed (Supplementary
Figures 1G–I).
Age Is the Strongest Determinant of
Performance by APOE4.Trem2*R47H Mice
in Behavioral Assays
As part of the comprehensive phenotypic characterization,
all mice were evaluated through a behavioral testing
pipeline consisting of open field, spontaneous alternation
(y-maze), rotarod motor coordination, and running wheel
activity assessments (Table 2; Supplementary Tables 2–5).
Age-dependent impairments were observed across all genotypes
from 4–24 months of age in locomotor activity as measured
by open field and entries in the y-maze, motor coordination as
measured by rotarod, and wheel- running activity (Figure 2;
Supplementary Figures 2, 4). Spatial working memory was
preserved up to 24 months of age with no deficits observed
across genotype relative to 4 months of age. Interestingly,
in the rotarod motor coordination assay, there was a greater
impairment observed in B6.Trem2*R47H males relative to
B6.APOE4.Trem2*R47H or B6.APOE4 alone at 24 months
(Figures 2A,B). Compared to 4-month-old animals, we
observed a decrease in activity during the active period
(dark phase) by 24 months (Supplementary Figure 4). At
24 months of age, home cage running wheel activity suggested a
correlation between increased activity during the active period
and expression of the APOEε4 allele (both B6.APOE4 and
B6J.APOE4/Trem2*R47H mice) by way of total distance traveled
and day-time activity in B6.Trem2*R47H mice (Supplementary
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TABLE 2 | Frailty assay and behavioral assays study population.
Mouse models 4M 8M 12M 24M
Male Female Male Female Male Female Male Female
C57BL/6J 16 16 18 18 23 21 12 9
APOE4 KI 12 12 12 12 11 10 11 11
TREM2* R47H 12 11 12 12 13 11 13 14
APOE4.TREM2* R47H 11 10 12 11 12 10 8 6
FIGURE 1 | Age is primary factor driving increases in measures of frailty. Cross-sectional cohorts of young and old mice inspected for measures of physical
well-being, or frailty (A,B), including body weight (C,D). Post-mortem, non-fasted, blood biochemistry analysis provided serum levels of cholesterol, lipoproteins,
lipids, and glucose (E–L). Age-dependent differences within genotype and sex determined by two-way ANOVA. Factor effects and effect interaction displayed in
tables. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001. All alleles expressed were homozygous.
Figures 4E,F). In addition to monitoring the physical wellness
and behavior of otherwise healthy mice, we also wanted to
track the effects of sex and genotype on animal longevity,
in the absence of amyloid-associated AD. For this analysis,
mortality was defined as subjects that were found dead with
no obvious signs of infection, trauma, or intervention during
daily monitoring. Mortality risk for each allele was determined
by comparing survival scores of cohorts aged upto 24 months.
Overall, females had a greater risk than males, and survival
probabilities were lowest in both sexes for animals expressing
both LOAD risk alleles (Supplementary Figure 5).
PET Identified Age- and
Genotype-Dependent Differences in
Glycolysis and Tissue Perfusion
In an effort to understand the role of risk alleles on regional
glycolysis and tissue perfusion, translationally relevant regional
measures were acquired via 18F-FDG and 64Cu-PTSM PET
and autoradiography, respectively (Figure 3). By 12 months
glycolysis was altered in key brain regions associated with
sensory integration, cognition, vision, and motor function in
B6.APOE4 and B6.APOE4.Trem2*R47H mice, when compared
with controls (Table 3; Supplementary Figure 6), and were
confirmed via post-mortem autoradiography, which has a
40-fold greater resolution than PET. As expected, these changes
were greater in number of regions and magnitude of change in
female mice when compared to males (Supplementary Figures
6B,C). These changes were similarly observed through time,
where female mice showed significantly altered glycolysis at 4, 8,
and 12 months, while male mice largely showed a hypoglycolytic
phenotype at 8months, that was virtually mitigated by 12months
(Supplementary Figure 6). Since these risk alleles can alter
metabolic functionality and neuroinflammatory-driven tissue
perfusion in an independentmanner, we quantitativelymeasured
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FIGURE 2 | Behavioral testing of LOAD mice to identify functional neurophenotype. Performance of young and aged mice carrying combinations of APOE4 and
Trem2*R47H alleles incorporated assays to measure neuromuscular coordination (rotarod; A,B), locomotor activity (open field; C–F), exploratory drive (open field;
G,H), and spatial working memory (spontaneous alternation in Y-maze; I–L). Age-dependent differences within genotype determined by two-way ANOVA. Factor
effects and effect interaction are displayed in tables. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗∗p < 0.001. All alleles expressed were homozygous.
changes in regional tissue perfusion via 64Cu-PTSM PET/MRI
and confirmed this via autoradiography. Brain perfusion was
significantly lower in regions associated with sensory integration,
cognition, vision, and motor function in both sexes by
12 months and confirmed via post-mortem autoradiography
(Supplementary Figure 7). Interestingly, these changes were
manifested temporally, with the greatest reductions occurring
across genotypes and regions in both sexes at 4 months
(Supplementary Figure 7). Unlike glycolysis, these changes
were largely resolved by 8 months in female mice, while
males continued to show a regional reduction in perfusion at
this same age. In 24-month-old animals, APOE4.Trem2*R47H
had increased glycolysis compared to C57BL/6J in most brain
regions, a trend that was also evident in young cohorts and in
both sexes (Figure 3A). Age-related increases in brain perfusion
were further confirmed in 24 months B6.APOE4.Trem2*R47H
mice (Figure 3B).
Biochemical and Neuropathological
Effects of APOEε4 and Trem2*R47H Alleles
Confirmation of protein expression levels in brain tissue
was confirmed for alleles encoding human APOE4 and
mouse TREM2 carrying the R47H mutation (Supplementary
Figure 8). Similar to reports of R47H variant-mediated
reduction in Trem2 transcript levels (Logsdon et al., 2019),
TREM2 protein levels in the brains of these animals were
also decreased. However, instead of a near knock-out of all
TREM2 that has been reported previously (Logsdon et al.,
2019), levels fell by approximately 50% in Trem2*R47H
animals compared to C57BL/6J (Supplementary Figures
8A,B). We have previously shown APOE4 protein levels
are similar to endogenous mouse APOE (Foley et al., 2020)
and expression of APOE4 appeared similar between male
and female APOE4.Trem2*R47H mice (Supplementary
Figure 8C). Additional molecular characterization of these
animals showed both age- and genotype-driven differences
in levels of cytokines present in the blood (Figure 4) and
brain (Supplementary Figure 9; Table 4). Compared to
similarly aged C57BL/6J and younger APOE4.Trem2*R47H
cohorts, 18 month B6.APOE4.Trem2*R47H mice showed strong
differences in circulating concentrations of immunomodulatory
cytokines (Figure 4). IL-6 and KC/GRO concentrations were
highest in B6.APOE4.Trem2*R47H brain tissue at 8 months,
while blood plasma concentrations continued to increase
with age in those mice (Supplementary Figures 9B,D,E).
On multiple occasions, a trend appeared to suggest increased
cytokine concentrations in mice expressing mutated allele
Trem2.
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FIGURE 3 | Increases in regional glucose metabolism due to expression of APOE4 and Trem2*R47H. Positron emission tomography (PET; red scale) of radioactive
18F-FDG marker was used to measure tissue glucose uptake, guided by computed tomography (CT; black and white) mapping to brain regions of interest, indicated
by bregma coordinates (far left) (A). PET-CT of 64-Cu PTSM of female and male B6.APOE4.Trem2*R47H mice revealed age-driven increases in brain perfusion (B).
Post-mortem autoradiography of coronal brain tissue is represented in (A) (rainbow; far right). Genotype- and age-dependent differences determined by three-way
ANOVA. Factor effects and effect interaction are displayed in tables. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001. All alleles expressed were homozygous.
Neuropathological features of AD were then investigated
by hematoxylin and eosin (H&E, structure) and luxol fast
blue/cresyl violet (LFB/CV, myelin) staining but did not
reveal any gross anatomical changes to tissue architecture
or myelin (Figure 5A). Brain sections were also imaged
via immunofluorescence and included neuritic plaque-
reactive-microglia (X34/Lamp1/Iba1), vascular leakage
(CD31/Iba1/Fibrin), and ThioflavinS (amyloid plaques and
neurofibrillary tau tangles; Figure 5B). No gross abnormalities
in cell counts (Figure 5C), nor additional neuropathological
features were observed in 24-month B6.APOE4.Trem2*R47H
mice. We focused particularly on the cortex and hippocampus
where episodic memory (hippocampus) and memory
behavior (cortex) are regulated. Amyloid plaques and
hyperphosphorylated Tau were not observed in mice of
any genotype at any age.
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FIGURE 4 | Levels of immunomodulatory cytokines in plasma are significantly different due to increased age and combined expression of APOE4 and Trem2*R47H
alleles. IFN-gamma (IFN-γ), IL-1beta, IL-10, IL-6, and KC/GRO (CXCL1) levels were measured by multiplex immunoassays of blood plasma from C57BL/6J and
B6.APOE4.Trem2R47H mice (A–F). Genotype- and age-dependent differences determined by two-way ANOVA. Factor effects displayed in tables. ∗p < 0.05;
∗∗p < 0.01; ∗∗∗p < 0.001. All alleles expressed were homozygous.
TABLE 3 | In vivo imaging study population.
Mouse models 4M 8M 12M
Male Female Male Female Male Female
C57BL/6J 8 9 12 11 9 10
APOE4 KI 10 10 10 12 12 10
TREM2*R47H 10 12 12 8 12 11
APOE4.TREM2* R47H 12 10 10 12 10 10
Transcriptional Profiling Revealed
Individual and Synergistic Effects of
APOEε4, Trem2*R47H, and Age
Brain hemispheres from 4 and 24-month male and female
B6.APOE4.Trem2*R47H mice and single genotype and
C57BL/6J controls were assessed using RNA-seq (see ‘‘Materials
and Methods’’ section; Table 5). The transcriptomic analysis
measured the expression levels (log-transformed TPM counts)
of mouse Apoe, Trem2, and human APOE genes across
all mouse models (Figures 6A–C). We observed higher
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TABLE 4 | Blood and brain tissue cytokine and metabolomic study population.
Mouse models 4M 8M 12M 24M
Male Female Male Female Male Female Male Female
C57BL/6J 17 13 12 6 10 11 15 13
APOE4 KI 11 10 11 12 13 14 10 10
TREM2*R47H 12 11 11 11 12 10 13 13
APOE4.TREM2*R47H 10 10 11 11 8 5 8 5
expression of human APOE gene in mice carrying humanized
APOEε4 (B6.APOE4 and B6.APOE4.Trem2*R47H mice),
whereas mouse Apoe gene was highly expressed in B6 and
Trem2*R47H mice (Figures 6A,B). As expected based on
protein levels (Supplementary Figures 7A,B), expression of
Trem2 was significantly reduced (p < 0.05) in B6.Trem2*R47H
and B6.APOE4.Trem2*R47H compared to age-matched B6
(Figure 6C), an effect likely caused by a novel effector splice site
and truncation introduced by the R47H mutation. Furthermore,
the expression level of Trem2 increased with age across all
mouse models, but no such patterns were observed in the
expression levels of mouse Apoe and human APOE genes
(Figures 6A,B). In addition, there was a lower expression of
Trem2 in B6.APOE4.Trem2*R47H compared to B6.Trem2*R47H
mice at an advanced age (24 months), suggesting expression
of Trem2 might be suppressed by APOEε4. Next, principal
component analysis (PCA) identified two distinct clusters
corresponding to male and female samples separated along with
the first principal component (26% of total variance), suggesting
sex-specific differences are profound in mice (Figure 6D).
Analysis of samples from different age groups revealed a
gradient of discrimination along with the second principal
component (14% of total variance; Figure 6D), implying the
presence of age-dependent molecular changes in the brain
transcriptomes.
To identify molecular effects of the LOAD risk genes, we
performed pairwise differential analysis between each genotype
(B6.APOE4, B6.Trem2*R47H or B6.APOE4.Trem2*R47H)
and age- and sex-matched B6 controls. At an early age
(4 months), only a few genes were differentially expressed (DEG;
p < 0.05) for all genotypes for both sexes (Supplementary
Figure 10A), and no KEGG pathways were enriched.
At 8 months of age, there were 32 DEGs (3 upregulated,
29 downregulated; p < 0.05) in male B6.Trem2*R47H mice,
and 11 DEGs (2 upregulated, 9 downregulated; p < 0.05)
in female B6.Trem2*R47H mice (Supplementary Figure
10A). KEGG Pathway analysis identified enrichment of genes
involved in immune-related pathways such as ‘‘complement and
coagulation cascades’’ and ‘‘staphylococcus aureus infection’’
in the downregulated DEGs in female B6.Trem2*R47H
mice (Figure 7). In 8 months old B6.APOE4 mice, a total
of 145 genes were significantly differentially expressed
(42 upregulated, 103 downregulated; p < 0.05) in male
mice, whereas a total of 25 genes were differentially expressed
(11 upregulated, 14 downregulated; p < 0.05) in female
mice (Supplementary Figure 10A). Pathway enrichment
analysis of upregulated genes in male B6.APOE4 mice
identified enrichment of ‘‘platelet activation’’ pathway,
whereas downregulated genes in female B6.APOE4 mice
were enriched for ‘‘protein processing in endoplasmic
reticulum’’ pathway (Figure 7). No KEGG pathways were
enriched for downregulated DEGs in male B6.APOE4 mice and
upregulated DEGs in female B6.APOE4 mice. DEGs in male
B6.APOE4.Trem2*R47H (7 upregulated, 32 downregulated),
and female B6.APOE4.Trem2*R47H mice (2 upregulated,
1 downregulated; p < 0.05; Supplementary Figure 10, Figure 7)
were not enriched in any KEGG pathway.
At 12 months of age, there were a total of 206 DEGs
(118 upregulated, 88 downregulated) in male B6.Trem2*R47H
mice and 285 DEGs (113 upregulated, 172 downregulated;
p < 0.05) in female B6.Trem2*R47H mice. The upregulated
DEGs in male Trem2*R47H mice were enriched in
‘‘RNA transport’’ and ‘‘spliceosome’’ pathways (Figure 7,
Supplementary Figure 10), while genes in the ‘‘oxidative
phosphorylation’’ pathway were downregulated in male
B6.Trem2*R47H mice (Figure 7, Supplementary Figure
10). Upregulated and downregulated DEGs in female
B6.Trem2*R47H mice were enriched for ‘‘RNA transport’’ and
‘‘lysosome’’ pathways respectively (Figure 7, Supplementary
Figure 10). There were very few DEGs in B6.APOE4 (1 in male,
3 in female) and B6.APOE4.Trem2*R47H mice (2 in male, 5 in
female; Supplementary Figure 10) at this age and therefore no
enrichment of KEGG Pathways.
At 24 months old, there were a total of 144 DEGs
(15 upregulated, 129 downregulated) in the male
B6.Trem2*R47H mice and 748 DEGs (359 upregulated,
389 downregulated; p < 0.05) in the female B6.Trem2*R47H
mice. At this age, B6.APOE4.Trem2*R47H mice showed
a greater number of DEGs (p < 0.05) in both male
(24 upregulated, 197 downregulated) and female mice
(83 upregulated, 400 downregulated) compared to at
younger ages (4–12 months; Supplementary Figure 10),
suggesting that the most dramatic transcriptional changes
arise between 12 and 24 months. We also found substantial
overlap in downregulated DEGs between B6.Trem2*R47H and
B6.APOE4.Trem2*R47H mice for both sexes (Supplementary
Figure 10). This suggests that the Trem2*R47H allele is the
major driving force in age-dependent transcriptional changes
in B6.APOE4.Trem2*R47H mice. Downregulated DEGs were
enriched in multiple AD-related pathways such as ‘‘lysosome’’,
‘‘osteoclast differentiation’’, ‘‘phagosome’’, ‘‘antigen processing
and presentation’’, cytokine-cytokine receptor interaction’, and
‘‘complement and coagulation cascades’’ in both 24 months old
B6.Trem2*R47H and B6.APOE4.Trem2*R47H mice (Figure 7,
Supplementary Figure 10). In B6.APOE4 mice, we observed
only two DEGs (1 upregulated, 1 downregulated) in male and
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FIGURE 5 | Neuropathological analysis of cortex and hippocampus. Hematoxylin and eosin (H&E), luxol fast blue/cresyl violet (LFB/CV), and Prussian blue staining
tissue staining protocols (A) to identify anatomical changes in the cortex and hippocampus of young and aged mice. Thioflavin S (Thios) and four combinations of
known neuropathological markers of LOAD in aged mice, 5xFAD included as amyloidogenic positive control (B). Neuropathological analysis of cortex and
hippocampus. Neuron (NeuN) cell populations were quantified in panel (C). Age- and genotype-dependent differences determined by two-way ANOVA. Factor
effects and effect interaction displayed in tables. *p < 0.05; **p < 0.01; ***p < 0.001. All alleles expressed were homozygous.
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TABLE 5 | RNA-seq study population.
Mouse models 4M 8M 12M 24M
Male Female Male Female Male Female Male Female
C57BL/6J 12 12 6 6 6 6 7 6
APOE4 KI 13 12 6 6 4 5 5 6
TREM2*R47H 12 12 6 6 6 6 6 3
APOE4.TREM2*R47H 10 12 5 6 8 5 7 6
24 DEGs (1 upregulated, 23 downregulated) in female mice.
Downregulated genes in the B6.APOE4 female mice were
enriched in ‘‘NOD-like receptor signaling’’ pathway (Figure 7,
Supplementary Figure 10). We did not observe any enriched
KEGG pathways in the upregulated list of genes across all
genotypes at 24 months.
Home Cage Voluntary Wheel Running
Increased Oxidative Phosphorylation
Pathway in APOE4.Trem2*R47H Mouse
Brains
In the human population, a sedentary lifestyle is correlated
with an increased risk of LOAD (de Rezende et al., 2014;
Fenesi et al., 2017; Yan et al., 2020). Therefore, to determine
if physical activity influenced transcriptional changes in
B6.APOE4.Trem2*R47H mice, a running wheel was provided
in the home cage of 22-month-old male mice for 2 months.
Brain tissue from these animals was profiled by RNA-seq.
A total of 292 DEGs (108 upregulated, 184 downregulated)
were identified in the running B6.APOE4.Trem2*R47H mice
compared to 24 months old B6 male mice. Enrichment
analysis identified multiple enriched KEGG pathways such as
‘‘oxidative phosphorylation’’, ‘‘thermogenesis’’, and ‘‘retrograde
endocannabinoid signaling’’ in the upregulated list of genes,
whereas immune system associated pathways were enriched in
the downregulated list of genes (Supplementary Figure 11A). To
identify the effect of exercise, running B6.APOE4.Trem2*R47H
male mice were compared with sedentary 24-month-old
B6.APOE4.Trem2*R47H male mice and there was a total
of 600 DEGs (312 upregulated, and 288 downregulated).
Upregulated DEGs were enriched in pathways such as ‘‘oxidative
phosphorylation’’ and ‘‘Ribosome’’ (Supplementary Figure
11A). The expression of these upregulated DEGs enriched for
oxidative phosphorylation showed reduced expression in age-
and sex-matched B6.APOE4 and B6.Trem2*R47H compared
to running B6.APOE4.Trem2*R47H mice (Supplementary
Figure 11B). Finally, the expression of the upregulated DEGs
associated with the oxidative phosphorylation pathway was
assessed in transcriptional data from AMP-AD. Reduced
expression of these running signature genes was observed in
AD cases compared to controls across multiple brain regions
such as parahippocampal gyrus (PHG) and frontal pole brain
regions (FP; Supplementary Figure 11C). This suggests that
exercise induces beneficial effects on health by increasing
the expression of oxidative phosphorylation pathway genes
that are down regulated across multiple brain regions in
AD patients.
DISCUSSION
MODEL-AD was established in response to the many
shortcomings of existing mouse models of AD. Aspects of
human pathology have been replicated in mouse strains,
most prominently the formation of beta-amyloid plaques via
transgenic over-expression of brain-specific mutant human
amyloid-beta precursor protein (APP), presenilin-1 (PS1),
and/or microtubule-associated protein tau (MAPT) bearing
familial Alzheimer’s disease (FAD) mutations (Bilkei-Gorzo,
2014). Legacy preclinical models rely heavily on alleles that
overexpress transgenes, resulting in the removal or masking of
important human-relevant biological interactions. These mouse
strains have been invaluable for understanding the molecular
and behavioral phenotypes of early-onset Alzheimer’s disease
(EOAD) driven by the rapid and robust formation of plaques
and tangles in the brain and correlating hyperactivity which
is a confound of many cognitive behaviors. However, LOAD
is ∼20× more prevalent than EOAD and further implicates
aging, inflammation, environmental, and many more genetic
risk factors in disease development. APOE4.Trem2*R47H mice
did not produce any severe phenotypes, even late into life,
allowing a better understanding of the effect of AD risk factors
in the context of aging (Supplementary Figure 5). As the
heterogeneity of this disease becomes more appreciated, so
is the importance of appropriate disease staging. Molecular
targets of interest may only be available during particular
evolving disease stages: debris (cell fragments, plaques,
tangles, etc.) accumulates over time, and inflammation,
interruption/loss of neuronal function all also change with
disease progression. In light of the repeated shortcomings of
‘‘fit-for-all’’ therapies, efforts may be better directed at targeted
therapies (Cummings et al., 2014, 2020; Safieh et al., 2019).
Faithfully modeling a complex, polygenic disease will be
aided by the creation of platform strains that carry multiple
genetic risk factors to motivate with a scientific rationale
rather than a grant-focused one. Of the candidate risk variants
identified, expression of the ε4 allele of APOE and the R47H
mutation in TREM2 were identified as the strongest candidates
for the initial development of a novel LOAD mouse strain.
Introduction of the R47H mutation into Trem2 resulted in
the creation of a novel murine splice site yielding a decrease
in approximately 50% of TREM2 protein (Supplementary
Figures 8A,B), and a 20% decrease in Trem2 transcript
(Figure 6C). In the absence of amyloid plaque insult, the effects
on microglia response due to the mutation and decreased
expression are difficult to decipher. Similar models have
shown similar decreases in R47H-mediated Trem2 expression
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FIGURE 6 | Overview of brain transcriptome. Expression levels of mouse Apoe (A), human APOE (B), and mouse Trem2 (C) genes in the B6.APOE4,
B6.Trem2*R47H, B6.APOE4.Trem2*R47H and C57BL/6J mice at 4, 8, 12, and 24 months in both sexes. Principal component analysis (PCA) of RNA-Seq
transcriptomics data from all 234 samples (D). The percent of variation explained by each principal component is displayed on the corresponding axis. Female and
male samples are represented as circles and triangles, respectively. Genotypes are shown by different colors and the increasing size of points correspond to the
increasing age of mice (4, 8, 12, and 24 months respectively). All alleles expressed were homozygous.
and function (Cheng et al., 2018; Cheng-Hathaway et al.,
2018; Xiang et al., 2018). Efforts are ongoing to develop
a Trem2 allele expressing the full-length R47H risk factor
at levels similar to wild-type Trem2. APOEε4 is strongly
associated with disease development and severity (Bu, 2009;
Yamazaki et al., 2019) and at least one allele is present in
approximately 65% of AD patients (Mayeux et al., 1998).
Unfortunately, endogenous Apoe in mice does not express
the isoform diversity seen from the APOE allele in humans.
Insertion of humanized APOE alleles into mouse genomes
has been a successful strategy to dissect the biology of APOE
isoforms in mice (Knouff et al., 1999; Esquerda-Canals et al.,
2017; Balu et al., 2019; Safieh et al., 2019; Lewandowski
et al., 2020). The MODEL-AD APOEε3 and APOEε4 allelic
series on a C57BL/6J background has subsequently be
shown to consistently reproduce the biology presented in
other APOE mouse models and most importantly, human
patients (Knouff et al., 1999; Foley et al., 2020). Therefore,
APOE4 formed the basis for multiple platform strains that
include: B6.APOE4.Trem2*R47H (for which we have provided
the identifier ‘‘LOAD1’’).
APOE binds to high-density lipoproteins to facilitate
cholesterol and phospholipid transport to LDL receptors. As
expected (Knouff et al., 1999; Maria Fe Lanfranco et al., 2020),
lipoprotein levels differed compared to endogenous Apoe, mice
expressing the humanized APOEε4 allele showed decreased
plasma lipoprotein levels across all time points (Supplementary
Table 2). We observed an age-dependent decrease in glucose
levels across both sexes and all genotypes (Figure 1L), an
indication of increased frailty and aging that is common
in aging-related-disease studies (Abdelhafiz et al., 2015). The
contributions of metabolic and vascular factors are strongly
implicated in disease progression, and how APOE or any
other metabolic trait, via systemic pathways, can influence CNS
function should be a continued focus for intervention (Zhao
et al., 2020). The brain has one of the richest networks of
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FIGURE 7 | KEGG pathways enrichment analysis. Significantly enriched KEGG pathways (p < 0.05) in the downregulated and upregulated list of genes across
mouse models at different ages for both sexes. All alleles expressed were homozygous.
blood vessels and is especially vulnerable (block or reduce
blood flow, oxygen, and nutrients). For example, the respective
influence of APOEε4, with and without Trem2*R47H expression,
in regional changes in brain glycolytic metabolism (Murray
et al., 2014; Figure 3, Supplementary Figure 6), tissue perfusion
(Thambisetty et al., 2010; Roher et al., 2012; Figure 4,
Supplementary Figure 7) observed in human AD remain under
further study. Additional analyses of this APOE4 allele have also
revealed changes in cholesterol metabolism and transcriptional
signatures in the brain compared to carriers of the APOE3 allele
(Foley et al., 2020).
Despite the heterogeneity of AD, age is the strongest risk
factor in the human population. As an aging disease, monitoring
and evaluating mouse models in relation to age is crucial
for understanding the onset and progression of the disease
over time. We selected timepoints that reflected different life
stages of an adult mouse: Mature, by 3–6 months (beyond
development but not yet affected by senescence); Middle-
aged, 10–14 months (some senescent changes detected in
some, not all, biomarkers of aging); and Aged, 18–24 months
(senescent markers can be observed in all animals; Fox et al.,
2007). Non-invasive testing of motor activity, behavior, and
cognition have been shown to be reliable phenotypes for
staging disease onset and trajectory (Sukoff Rizzo et al.,
2018; Bogue et al., 2020). Aged mice equally displayed
the expected trial-dependent increases in consecutive rotarod
trials and decrease in total distance traveled over time in
the open field assay, regardless of genotype (Supplementary
Figure 3). Animal activity, measured by total distance traveled
during open field assays (Figure 2, Supplementary Figure
2), also decreased equally with age. Similarly, home cage
wheel running assays, which provide a more comprehensive
activity phenotype than the 1-h open field test, also showed
a decrease in activity levels during the active (dark phase;
Sukoff Rizzo et al., 2018; Supplementary Figure 4). Interestingly,
at 24 months some indications of increased activity during
the active phase in animals carrying the APOEε4 allele (both
B6.APOE4 and B6J.APOE4/Trem2*R47H) and day-time activity
in only B6.Trem2*R47H mice suggesting a dominant phenotype
produced by expression of APOEε4 (Supplementary Figures
4C,D, 10). Further consideration of genotype influences in
behavioral, biometric, and molecular testing by statistical
analysis was restricted by breeding strategy. Only littermate
animals are considered for statistical comparisons, preventing
C57BL6/J and B6.Trem2*R47H animal genotypes from inclusion
within timepoints.
In the absence of additional environmental or genetic
risk factors, B6.APOE4/Trem2*R47H mice did not display
penetrant behavioral phenotypes beyond the expected aging-
related changes but did exhibit decreased survival probabilities
by 24 months (Supplementary Figure 5). Very few C57BL/6J
mice succumbed during the 24-month aging process (<5%),
whereas mortality was higher in mice expressing both LOAD
alleles in both males (∼20%) and females (∼35%). Male mice
expressing either allele alone had survival probabilities similar
to C57BL/6J, whereas females with APOEε4 or Trem2*R47H
showed a mortality rate of ∼20%. Therefore, it would seem that
these two LOAD risk alleles show an equal and additive risk
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when expressed together, but in females, their interaction appears
synergistic.
We investigated the molecular signatures in the brain
transcriptomes of LOAD mouse models at different ages in both
sexes.We identified age-dependentmolecular changes associated
with LOAD pathologies in mouse models. Introduction of the
R47H mutation revealed a novel Trem2 isoform identical to
the primary transcript, but truncated by 119 bp from its start
position in exon 2 (see ‘‘Materials and Methods’’ section;
Kotredes, 2020). Expression of this novel isoform resulted in a
decrease in both transcript and protein compared to wild-type
Trem2 carriers (Figure 6C, Supplementary Figures 8A,B).
Despite the decrease in Trem2 expression, mouse models
carrying R47H mutation in the Trem2 gene did not exhibit any
significant transcriptional changes at a young age, in contrast,
APOE4 mice exhibited significant changes only at 8 months
of age. We further identified significant downregulation of
genes associated with oxidative phosphorylation pathway in the
12 months old B6.Trem2*R47H mice, suggesting that oxidative
phosphorylation could be prominent early feature for the onset
of neurodegeneration/inflammation process. Subsequently,
multiple immune-related processes were disrupted in 24 months
old B6.Trem2*R47H and B6.APOE4.Trem2*R47H mice,
supporting the profound relationship between aging, Trem2, and
AD. Interestingly, at 12 months of age, we did not observe any
significant transcriptional changes in B6.APOE4.Trem2*R47H
mice compared to control mice, suggesting that the effect of
Trem2 gene is suppressed due to the presence of APOEε4.
Similarly, when mouse models were compared with human
co-expression modules, we observed a strong negative
correlation between the B6.Trem2*R47H mice and immune-
related human co-expression modules from multiple brain
regions and this inflammatory response is dampened in
the presence of APOEε4 in the B6.APOE4.Trem2*R47H mice.
Distinctmousemodels showed concordance with distinct human
co-expression modules reflecting a different transcriptional
response driven by the human APOEε4 and Trem2*R47H risk
variants. We also observed age-dependent shift in co-expression
patterns associated with LOAD pathologies. A strong negative
correlation between co-expression modules associated with
cell cycle and DNA repair was observed in the early-aged
mouse B6.APOE4 model, whereas advanced-aged B6.APOE4
female mice showed a strong positive correlation with these
co-expression modules. This overlap with human late-onset
co-expression signatures early in life was observed for a number
of different brain regions and was absent in Trem2*R47H
knock-in mice. Furthermore, aged B6.Trem2*R47H mice
showed a moderate overlap with several human neuronal
co-expression modules enriched for genes that play an important
role in synaptic signaling and myelination. At an advanced age,
a strong correlation between the mouse models and immune-
related human co-expression modules highlights the important
role of the LOAD-associated APOEε4 and TREM2 R47H variant
in Alzheimer’s related immune processes. Our experiments
predict that APOEε4 functions through the suppression of effects
brought out by expression of theTrem2*R47H allele, displayed by
the 455 genes that are upregulated by TREM2R47H but suppressed
byAPOEε4 (Supplementary Figure 10). Our resultsmirror some
emerging evidence that APOEε4 suppresses Trem2*R47H in AD
risk, that there are some suggestions that APOEε4 carriers do
not have increased AD risk with Trem2*R47H and Trem2*R47H
only increases the risk onAPOEε3 carriers (Jendresen et al., 2017;
Fitz et al., 2020). Additionally, we observe more differentially
expressed genes at middle age than at a later age supporting
evidence of an earlier aging phenotype than C57BL/6J mice, with
a realignment of transcriptomes at later timepoints (McGeer
et al., 1997; Zhao et al., 2020). We employed a weighted gene
co-expression network analysis (WGCNA) used to identify
modules of correlated genes. Each module was tested for
differential expression by strain, then compared with human
postmortem brain modules from the Accelerating Medicine’s
Partnership for AD (AMP-AD) to determine the LOAD-related
processes affected by each genetic risk factor (Logsdon et al.,
2019; Pandey et al., 2019; Wan et al., 2020). This will be a useful
tool in identifying differentially expressed genes correlated with
molecular pathways tied to inflammation and identifying a
mouse strain that exhibits a similar transcriptional signature to
human patients with true neuroinflammation.
Amyloid plaque formation is a primary diagnostic measure
of Alzheimer’s disease with both APOE and TREM2 linked
to amyloid deposition (McGeer et al., 1997; Blennow et al.,
2006; Bilkei-Gorzo, 2014; Kanekiyo et al., 2014; Jay et al.,
2015; Cacace et al., 2016; Dourlen et al., 2019; Parhizkar
et al., 2019). For example, TREM2 can bind amyloid, altering
microglial function, linking the TREM2-APOE pathway directly
to amyloid-driven disease progression (Zhao et al., 2018;
Kober et al., 2020). Loss of functional Trem2 in mice resulted
in plaques that contained reduced amounts of APOE and
promoted amyloidogenesis in mice by reducing microglial
function (Parhizkar et al., 2019; McQuade et al., 2020)
indicating that microglia, through TREM2 mediated signaling,
can regulate APOE co-deposition around amyloid deposits.
Further, TREM2 KO prevented infiltration of blood-derived
myeloid cells and ameliorated plaque burden in APP/PS1 mice
(Jay et al., 2015) and disease-related mutations impair many of its
functions (Kober et al., 2016). However, current amyloidogenic
mouse models develop amyloid plaques at very young ages,
within a few months (Supplementary Figure 7B), whereas
in human patients the average age of AD onset is at older
ages, ∼80 years, potentially causing the disparity in therapeutic
outcomes between mouse models and human patients. In the
absence of amyloid deposition, many hallmarks of LOAD can
be investigated for APOEε4- and Trem2-influenced effects that
precede and may contribute to the onset of AD. However,
current work is evaluating the effects of APOE and TREM2 risk
alleles in the context of humanized Abeta. For instance, we
are currently evaluating a novel B6.APOE4.Trem2*R47H.hAbeta
(LOAD2) strain and in the process of incorporating humanized
Tau (MAPT) alleles into forthcoming strains. These novel
platforms or AD-sensitized strains (e.g., LOAD1, LOAD2,
etc.) are being used to assess the contribution of additional
genetic risk factors identified through genetic and genome-wide
association approaches using LOAD1 as a platform strain.
These include variations in genes commonly associated with
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AD including ABCA7, PLCG2, CR1, BIN1, and SORL1. The
new strains are prioritized for extensive phenotyping using
a primary screening approach centered on transcriptional
profiling of nearly 800 genes known to be differentially
expressed in human AD brains compared to unaffected controls
(Preuss et al., 2020). Platform strains are also ideal for
studying age-dependent effects of environmental risk factors,
such as diet, as well as genetic context. Deeper analysis of
APOE4.Trem2*R47H transcriptional data, in vivo imaging, and
neuropathology samples are continuing and will be detailed in
future publications. Amendments to the current phenotyping
strategy are also in consideration to expand characterizations
of the metabolome, proteome, and electrophysiology of LOAD
animals. In subsequent studies utilizing new mouse strains, the
utility of the APOE4.Trem2*R47H datasets will grow. Ultimately,
strains carrying combinations of risk factors that more closely
align with the human disease will be incorporated into the
pre-clinical testing core of MODEL-AD to assess the potential
of prioritized compounds to treat AD.
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